VENTOLIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VENTOLIN (VENTOLIN).
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP
| Metabolism | Primarily hepatic via conjugation; substrate for catechol-O-methyltransferase (COMT) and sulfation; minor CYP450 metabolism |
| Excretion | Renal (60-70% as unchanged drug and metabolites), biliary/fecal (minor, <10%) |
| Half-life | Terminal elimination half-life 3-4 hours (nebulized, oral); 4-6 hours (intravenous); prolonged in renal impairment |
| Protein binding | Approximately 10-15% (primarily to albumin) |
| Volume of Distribution | 2-4 L/kg (extensive extravascular distribution, minimal CNS penetration) |
| Bioavailability | Inhalation: 10-20% (delivered dose to lungs); Oral: 40-50% (extensive first-pass metabolism) |
| Onset of Action | Inhalation: 5-15 minutes; Oral: 30-60 minutes; Intravenous: immediate |
| Duration of Action | Inhalation: 4-6 hours (short-acting beta-agonist); oral: 4-8 hours; sustained-release oral: 12 hours |
| Molecular Weight | 239.31 |
2 inhalations (100 mcg/inhalation) via metered-dose inhaler every 4-6 hours as needed for bronchospasm. For nebulization: 2.5 mg (0.5 mL of 0.5% solution) in 2.5 mL sterile normal saline, inhaled via nebulizer 3-4 times daily.
| Dosage form | SYRUP |
| Renal impairment | No specific dose adjustment required for renal impairment. Dose as in normal renal function. |
| Liver impairment | No specific dose adjustment required for hepatic impairment. Dose as in normal hepatic function. |
| Pediatric use | For acute bronchospasm: Children <12 years: 1-2 inhalations (100 mcg/inhalation) via MDI every 4-6 hours as needed, or via nebulizer: 0.15 mg/kg/dose (minimum 2.5 mg) every 4-6 hours. Maximum 10 mg/day. |
| Geriatric use | No specific dose adjustment; use caution in patients with cardiovascular disease. Start at lower end of dosing range (e.g., 1 inhalation) and titrate to effect. |
| 1st trimester | Animal studies have shown no evidence of teratogenicity. Limited human data; but widely used without reported increase in malformations. Use if clearly needed. |
| 2nd trimester | No known fetal risk. Monitor maternal asthma control; untreated asthma may cause maternal/fetal hypoxia. |
| 3rd trimester | May cause transient fetal tachycardia and hypoglycemia if used near term. Beta-agonists may inhibit labor; use with caution. |
Clinical note
Comprehensive clinical and safety monograph for VENTOLIN (VENTOLIN).
| Placental transfer | Crosses placenta; fetal serum levels approximately 10-20% of maternal levels. |
| Breastfeeding | Albuterol is excreted into breast milk in small amounts (estimated 0.5-3% of maternal weight-adjusted dose). No adverse effects reported in infants. Considered compatible with breastfeeding; monitor for infant tachycardia or irritability. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to albuterol or any componentStatus asthmaticus (not appropriate for acute severe deterioration without additional therapy)
| Precautions | Paradoxical bronchospasm may occur; discontinue immediately, Cardiovascular effects: increased heart rate, blood pressure, QT prolongation; use caution with cardiovascular disorders, Hypokalemia may occur (especially with high doses), Immediate hypersensitivity reactions (urticaria, angioedema, rash), Do not exceed recommended dose; excessive use may lead to death |
| Food/Dietary | No significant food interactions. Avoid high-sugar foods if using high doses due to possible hyperglycemia. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Inhaled short-acting beta-agonists like albuterol are not associated with increased risk of major congenital malformations. First trimester: no increased risk in observational studies. Second and third trimesters: may cause maternal tachycardia, hyperglycemia, and fetal tachycardia; no known teratogenic effects. Use during labor may delay preterm labor and cause neonatal hypoglycemia or hypokalemia. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and serum glucose. Fetal heart rate monitoring should be considered during acute use, especially in third trimester or preterm labor. Assess for signs of maternal hypokalemia with high-dose therapy. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. Albuterol is not associated with impairment of male or female reproductive function. |
| Clinical Pearls |
| First-line for acute asthma exacerbation; use with spacer for better lung deposition; monitor for hypokalemia and hyperglycemia at high doses; tachyphylaxis with regular use; not for long-term control. |
| Patient Advice | Use only as needed for symptom relief, not daily. · Rinse mouth after use to prevent thrush. · Shake inhaler before each use. · If using more than twice weekly, see doctor. · Seek emergency if no relief after 2 puffs. |